[Radiotherapy with androgen deprivation in high-risk prostate cancer: what outcomes on a Caribbean population?].

[1]  F. García-Vicente,et al.  Long-term results after high-dose radiotherapy and adjuvant hormones in prostate cancer: how curable is high-risk disease? , 2011, International journal of radiation oncology, biology, physics.

[2]  P. Muti,et al.  Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: Meta-analysis of randomized trials , 2010, BMC Cancer.

[3]  C. L. Cutajar,et al.  External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. , 2010, The Lancet. Oncology.

[4]  M. Kattan,et al.  Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature. , 2010, European urology.

[5]  B. Jégou,et al.  Chlordecone exposure and risk of prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  John D. Roberts,et al.  Do African American Men Have Lower Survival From Prostate Cancer Compared With White Men? A Meta-analysis , 2010, American journal of men's health.

[7]  M. Banerjee,et al.  Interplay of race, socioeconomic status, and treatment on survival of patients with prostate cancer. , 2009, Urology.

[8]  R. Peschel,et al.  Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma. , 2009, International journal of radiation oncology, biology, physics.

[9]  N. Zaffaroni,et al.  Biomolecular markers of outcome prediction in prostate cancer , 2009, Cancer.

[10]  A. D'Amico,et al.  Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors. , 2009, International journal of radiation oncology, biology, physics.

[11]  G. Verhoest,et al.  [Prostate cancer in Guadeloupe (French West Indies): incidence, mortality and clinicopathological features]. , 2009, Bulletin du cancer.

[12]  Y. Ben-Shlomo,et al.  Investigating Black‐White differences in prostate cancer prognosis: A systematic review and meta‐analysis , 2008, International journal of cancer.

[13]  Yoshiya Yamada,et al.  Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. , 2008, International journal of radiation oncology, biology, physics.

[14]  Charles R. Thomas,et al.  An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. , 2007, International journal of radiation oncology, biology, physics.

[15]  I. Powell.  Epidemiology and pathophysiology of prostate cancer in African-American men. , 2007, The Journal of urology.

[16]  A. Renshaw,et al.  The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer. , 2001, International journal of radiation oncology, biology, physics.

[17]  M. Banerjee,et al.  Prostate cancer biochemical recurrence stage for stage is more frequent among African-American than white men with locally advanced but not organ-confined disease. , 2000, Urology.

[18]  L. Salomon,et al.  [Recommendations Onco-Urology 2010: Prostate cancer]. , 2010, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

[19]  R. Weichselbaum,et al.  Equivalent racial outcome after conformal radiotherapy for prostate cancer: a single departmental experience. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.